SHANGHAI, China, April 30 /Xinhua-PRNewswire/ -- Today, Tigermed Consulting Ltd. joins Sundia Meditech, HD BioSciences, and NovaSecta in their CRO Service Alliance CROSA that provides R&D solutions for pharmaceutical and biotech companies. Tigermed's expertise in clinical development complements the existing drug discovery and pharmaceutical development capabilities of the alliance.
Sundia Meditech, United PharmaTech, and HD BioSciences entered into a CRO Service Alliance in May 2007 in order to quickly and successfully integrate their chemistry and biology expertise for the increased demands from their clients world-wide. Sundia and United merged into one company in the following months. NovaSecta joined the alliance in February 2008 to further integrate the alliance's work with European pharmaceutical and biotech companies.
Tigermed has a strong track record of providing clinical development services, data management and statistical support to multinational and smaller to medium sized pharmaceutical and biotech companies in US, Europe and Asia. Tigermed is also the clear leader in performing clinical trials in China on innovative New Chemical Entities (NCEs), which makes it an excellent potential partner for the pharmaceutical and biotech companies that Sundia, HD BioSciences and NovaSecta work with.
Through the addition of Tigermed to the alliance, clients can now benefit from a seamlessly integrated full R&D service covering discovery, non-clinical and clinical development.
About Sundia Meditech ( http://www.sundia.com )
Sundia MediTech was founded in Shanghai in 2004 by veterans of the US
pharmaceutical industry, and is now a leading CRO company in China. The
founding team has talent and track record in organic synthesis, medicinal
chemistry, drug design and discovery, process chemistry, cGMP API
production, in vitro/vivo PK research, formulation development, analytical
|SOURCE Sundia MediTech Company|
Copyright©2008 PR Newswire.
All rights reserved